Novel Respiratory Training as Part of Palliative Care for Older Adults With Heart Failure (RETRO)

July 3, 2025 updated by: Daniel Forman, MD, University of Pittsburgh

In a randomized controlled trial, to study the utility of inspiratory muscle training (IMT) to improve functional outcomes in adults aged ≥70 years with heart failure (HF) who have been referred to palliative care for end-stage HF management.

  • The study team hypothesize that older HF patients will be able to use IMT safely, reliably, and effectively in a 12-week home-based training regimen.
  • The study team hypothesize that physical function (sit to stand, gait speed, grip strength), respiratory/pulmonary function, self-efficacy, fatigue and quality of life will increase among older HF patients randomized IMT versus those randomized to usual care.

Study Overview

Detailed Description

Heart failure (both HF with reduced ejection fraction [HFrEF] and HF with preserved ejection fraction [HFpEF]) are on the rise in our aging population. Exercise intolerance is a leading detriment of the disease. While it is understood that exercise training is beneficial, strategies to achieve exercise training in this population are inherently limited, particularly as the issues that contribute to HF pathophysiology (i.e., advanced age, frailty, multimorbidity) also predispose to sedentariness, weakening, frailty, sarcopenia, fatigue, and cognitive impairment. Physical activity and particularly exercise training may be hard to initiate and sustain especially because it is encumbered by limitations. Home-based exercise training strategies are conceptually appealing in respect to practicality of access, but the associated issues of monitoring for effective and safe exercise, motivation, and tracking of training are all difficult to achieve in a home-based format. Furthermore, many older adults lack suitable space or resources for traditional home-based exercise training.

IMT with the PrO2™ device responds to these challenges with a novel approach to achieve physiologically robust training effect (strength training of the diaphragm) in a way that mitigates breathlessness and augments multiple indices of function in a way that is practical and safe, even at home. The electronic dimensions of the device also enable embedded trackability and behavioral prompts. Overall, this is a novel approach to a common, familiar problem, and it responds directly to a well-known problem of dyspnea, sedentariness and related functional decline that undermines current standards of HF care.

Existing models of exercise training for HF rely primarily on site-based regimens of aerobic and strength training modalities. Implementation barriers include unfeasible logistics for patients who often do not drive, particularly as many older patients struggle with frailty as well as limitations due to cognitive decline, sensory impairment, and/or socioeconomic challenges amidst the predictable complexities associated with advanced age. Fear and poor motivation compound these limitations, with limited options to motivate, supervise, and track progress for many candidates.

This proposal promotes the concept of "Palliative Care Rehab" which is transformational in concept. It shifts the premise of cardiac rehabilitation from cardiorespiratory fitness to more rudimentary goals of activities of daily living and self-efficacy. Likewise, rather than focusing on traditional cardiovascular endpoints of exercise testing and high performance, this study is oriented to submaximal endpoints, fatigability, and qualitative metrics.

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15213
        • University of Pittsburgh

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Patients with Advanced Heart Failure (HFrEF or HFpEF), with NYHA class II, III, or IV despite a minimum of
  • 6 weeks of treatment
  • Age >70 years
  • Male and Female
  • Optimal therapy according to AHA/ACC and HFSA HF guidelines

Exclusion Criteria:

  • Patients living in an institutional setting (e.g., skilled nursing home) during the intended period of this study.
  • Major cardiovascular event or procedure within the prior 6 weeks.
  • HF secondary to significant uncorrected primary valvular disease (except mitral regurgitation secondary to left ventricular dysfunction). If valve replacement has been performed, the participant may not be enrolled for 12 months after this procedure.
  • Dementia
  • Severe COPD (FEV1<50%), PVD, and/or Anemia
  • End-stage malignancy
  • Severe valvular heart disease
  • Psychiatric hospitalization within the last 3 months
  • Chronic ETOH or drug dependency.

We will exclude all of the following special populations:

  • Adults unable to consent
  • Individuals who are not yet adults (infants, children, teenagers)
  • Pregnant women
  • Prisoners

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Standard of Care
Participants in the usual care group will be telephoned at 4 and 8 weeks, and AE/SAE will be reviewed.
Standard of Care Participants in the usual care group will be telephoned at 4 and 8 weeks, and AE/SAE will be reviewed.
Experimental: IMT Group: Inspiratory Muscle Training (IMT)
IMT exercise sessions addition to standard of care.
IMT using a PrO2™ inspiratory training device will incorporate the Test of Incremental Respiratory Endurance (TIRE)9 technology to achieve an optimized exercise training regimen.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Safety of a 12-week home-based IMT program.
Time Frame: Baseline and weekly for 12 weeks
AE/SAE (IMT vs. controls): number Completion of the 3-month intervention (IMT vs. controls)
Baseline and weekly for 12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adherence to IMT training sessions
Time Frame: Baseline and weekly for 12 weeks
Number of IMT sessions competed over 12-week intervention
Baseline and weekly for 12 weeks
Improvement in MIP
Time Frame: Baseline, 12 weeks
Improvement in MIP (IMT vs. controls): cm H2O
Baseline, 12 weeks
Sit to stand
Time Frame: Baseline, 12 weeks
5-times Sit-to-Stand: seconds
Baseline, 12 weeks
Gait speed
Time Frame: Baseline, 12 weeks
4 m Gait Speed: m/sec
Baseline, 12 weeks
Grip strength
Time Frame: Baseline, 12 weeks
Grip Strength: pounds
Baseline, 12 weeks
Self-efficacy
Time Frame: Baseline, 12 weeks
Self-efficacy: Sullivan Self-Efficacy; 0-52; higher score is more favorable
Baseline, 12 weeks
Quality of Life
Time Frame: Baseline, 12 weeks
Quality of Life: Kansas City Cardiomyopathy Questionnaire (KCCQ): score 0-100; higher is more favorable than lower score.
Baseline, 12 weeks
Fatigue
Time Frame: Baseline, 12 weeks
Fatigue: PROMIS Item Bank v1.0 - Fatigue - short form 13a (FACIT-Fatigue): scale 0-52; lower indicates less fatigue.
Baseline, 12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Daniel E. Forman, M.D, University of Pittsburgh

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 30, 2024

Primary Completion (Actual)

February 28, 2025

Study Completion (Estimated)

February 28, 2026

Study Registration Dates

First Submitted

February 22, 2024

First Submitted That Met QC Criteria

August 26, 2024

First Posted (Actual)

August 28, 2024

Study Record Updates

Last Update Posted (Actual)

July 4, 2025

Last Update Submitted That Met QC Criteria

July 3, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Hope to publish results of this pilot study.

IPD Sharing Time Frame

Data will be available one year after study is closed.

IPD Sharing Access Criteria

Per PI discretion

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Quality of Life

Clinical Trials on Standard of Care

Subscribe